ANGLE plc (GB:AGL) has released an update.
ANGLE plc announced a study showcasing that their Parsortix system can potentially predict progression-free survival in ovarian cancer drug trials. The study analyzed 474 blood samples from 123 metastatic ovarian cancer patients, finding that certain genetic markers in circulating tumor cells could indicate the likelihood of disease progression. These findings may help in monitoring patient responses in pharmaceutical trials and contribute to the understanding of ovarian cancer treatment.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
